GAPDHP40

Across TCGA pan-cancer cohorts, GAPDHP40 RNA differs between tumor and matched normal tissue in 13 of 18 cancer types tested, making tumor–normal expression one of GAPDHP40’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where GAPDHP40 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types GAPDHP40 is over-expressed in tumor.

KIRC, COAD, and LUSC are the cancer types where GAPDHP40 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in GAPDHP40 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Female	IV	+1.276	<.001	12	view →
COAD	Female	II,III,IV	+1.902	<.001	9	view →
LUSC	Female	All	+0.696	<.001	8	view →
KIRP	Male	III,IV	+0.646	<.001	8	view →
LUAD	Female	All	+0.481	<.001	8	view →
HNSC	Male	II,III,IV	+0.440	<.001	7	view →
UCEC	All	All	+1.314	<.001	6	view →
BRCA	All	II,III,IV	+0.345	<.001	6	view →
THCA	Female	II,III,IV	+0.339	.001	6	view →
READ	All	II,III,IV	+0.505	.003	5	view →
LIHC	Female	All	+0.260	<.001	5	view →
STAD	All	II,III,IV	+0.306	.040	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 13 lineages.

GAPDHP40–KIRC

Open the KIRC breakdown →